Is the Laotian version of Sotorasibu effective? Comparative analysis of effects and genuine products

Sotorasib (AMG510, Sotorasib) is the first approved KRAS G12C inhibitor, developed by Amgen. It is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations, especially those who have progressed after previous systemic treatment. Since being approved by the U.S. FDA in 2021, the drug has been approved in many countries and regions such as the European Union, the United Kingdom, and Japan, becoming a breakthrough drug for targeted treatment of KRAS mutations.

With the widespread use of sotorasibu around the world, some generic drugs have also come out one after another. Among them, the Lao version of sotorasibu (such as produced by Lucius Pharmaceutical Factory, Daxiong Pharmaceutical Factory, United Pharmaceuticals, etc.) has attracted the attention of some patients because of its lower price than the original drug. Due to the higher price of original drugs, some patients with limited financial conditions may consider Lao generic drugs as an alternative. So, is the efficacy of the Laotian version of sotorasibu reliable? What are the differences compared with the original product?

The main ingredient of the Lao version of Sotorasib is basically the same as the original drug. It is also the sameSotorasib can theoretically play a similar role, that is, it can irreversibly bind to the KRAS G12C mutant protein and block its signal transduction, thereby inhibiting the growth of cancer cells. Therefore, from the perspective of drug ingredients, Laotian generic drugs should have the same molecular structure as the original drugs and can produce a certain anti-tumor effect.

The price of the Lao version of sotorasibu is lower than that of the original drug. Currently on the marketThe price of 120 mg × 56 tablets per box is about more than 1,000 yuan, while the price of the original drug is usually much higher than this level. Therefore, for patients with limited financial capabilities, generic drugs provide a relatively affordable treatment option. However, patients need to comprehensively consider efficacy, quality assurance and safety when choosing. Especially in anti-cancer treatments that may affect survival, safety and efficacy should be the primary considerations.

Reference materials:https://www.lumakras.com/